Diagnostic Medical Systems S.A. operates in the medical imaging industry in France.
Adequate balance sheet and overvalued.
Share Price & News
How has Diagnostic Medical Systems's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DGM has not had significant price volatility in the past 3 months.
7 Day Return
FR Medical Equipment
1 Year Return
FR Medical Equipment
Return vs Industry: DGM underperformed the French Medical Equipment industry which returned 75.4% over the past year.
Return vs Market: DGM exceeded the French Market which returned -4.8% over the past year.
Price Volatility Vs. Market
How volatile is Diagnostic Medical Systems's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StInvestors Who Bought Diagnostic Medical Systems (EPA:DGM) Shares Five Years Ago Are Now Down 47%
6 months ago | Simply Wall StWould Diagnostic Medical Systems (EPA:DGM) Be Better Off With Less Debt?
8 months ago | Simply Wall StDid You Miss Diagnostic Medical Systems's (EPA:DGM) 73% Share Price Gain?
Is Diagnostic Medical Systems undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate DGM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate DGM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: DGM is unprofitable, so we can't compare its PE Ratio to the FR Medical Equipment industry average.
PE vs Market: DGM is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DGM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DGM is good value based on its PB Ratio (1.7x) compared to the FR Medical Equipment industry average (3.1x).
How is Diagnostic Medical Systems forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Diagnostic Medical Systems has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Diagnostic Medical Systems's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Diagnostic Medical Systems competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Diagnostic Medical Systems performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DGM is currently unprofitable.
Growing Profit Margin: DGM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DGM is unprofitable, and losses have increased over the past 5 years at a rate of 38% per year.
Accelerating Growth: Unable to compare DGM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DGM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-8%).
Return on Equity
High ROE: DGM has a negative Return on Equity (-21.82%), as it is currently unprofitable.
How is Diagnostic Medical Systems's financial position?
Financial Position Analysis
Short Term Liabilities: DGM's short term assets (€24.0M) exceed its short term liabilities (€22.0M).
Long Term Liabilities: DGM's short term assets (€24.0M) exceed its long term liabilities (€3.5M).
Debt to Equity History and Analysis
Debt Level: DGM's debt to equity ratio (62.4%) is considered high.
Reducing Debt: DGM's debt to equity ratio has increased from 21.8% to 62.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DGM has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: DGM is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.
What is Diagnostic Medical Systems's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DGM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DGM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DGM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DGM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DGM's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Mr. Jean-Paul Ansel serves as the Chief Executive Officer of Diagnostic Medical Systems S.A. and has been its Chairman since 2010. He serves as a Director of Diagnostic Medical Systems S.A. Mr. Ansel serve ...
CEO Compensation Analysis
Compensation vs Market: Jean-Paul's total compensation ($USD223.95K) is about average for companies of similar size in the French market ($USD313.53K).
Compensation vs Earnings: Jean-Paul's compensation has been consistent with company performance over the past year.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Diagnostic Medical Systems S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Diagnostic Medical Systems S.A.
- Ticker: DGM
- Exchange: ENXTPA
- Founded: 1993
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €25.148m
- Shares outstanding: 16.12m
- Website: https://www.dms.com
Number of Employees
- Diagnostic Medical Systems S.A.
- 393 rue Charles Lindbergh
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|DGM||ENXTPA (Euronext Paris)||Yes||Ordinary Shares||FR||EUR||May 1998|
|0RIA||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||EUR||May 1998|
|DGMP||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||EUR||May 1998|
Diagnostic Medical Systems S.A. operates in the medical imaging industry in France. It offers radiography/fluoroscopy, retrofit kits, mammography, chest and bone rooms, mobiles, bone densitometry, 3D recon ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/08 22:13|
|End of Day Share Price||2020/08/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.